MedTrace Logo

Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

NCT00435370 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2017-03-15

Study results available
· View outcomes & findings →

Summary

This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.

Conditions

Interventions

DRUG

Tropisetron

10 mg/day

DRUG

Placebo

placebo

DRUG

Risperidone

6mg/day

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Thomas Kosten, MD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2011-02-28
Completion
2011-08-31

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00435370 on ClinicalTrials.gov